IP Cases — 2024
6,517 decisions across all jurisdictions
Page 7 of 218 · 6,517 total
Tesla, Inc. v.Intellectual Ventures II LLC
Tesla has filed an IPR petition seeking to invalidate five claims of Intellectual Ventures’ U.S. Pat. 7,181,743. The challenger argues the claims are obvious over the Welch whitepaper and related publications, and disputes any discretionary denial.
Intel Corporation v.Proxense, LLC
Intel has filed an IPR petition seeking to invalidate Proxense’s ’672 patent covering wireless time‑slot allocation, arguing the claims are obvious over public standards and prior‑art publications.
Intel Corporation v.Proxense, LLC
Intel has filed a petition to invalidate Proxense’s U.S. Patent 8,219,129 covering high‑rate WPAN communications, asserting obviousness over a combination of prior‑art references.
Intel Corporation v.Proxense, LLC
Intel has filed an IPR petition challenging Proxense’s 9,265,043 patent covering wireless time‑slot allocation. The petition asserts obviousness over combinations of Gilb, IEEE 802.15.3, Ward, and Brawn, and argues discretionary denial is improper.
Twitch Interactive, Inc. et al. v.Razdog Holdings LLC
Twitch Interactive has filed a petition to invalidate claim 1 of Razdog’s cloud‑computing patent, arguing obviousness over three prior‑art references and seeking institution of an IPR trial.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody successfully challenged Hyperice's patent claims in a PTAB proceeding focused on massaging devices. The Board found likelihood of unpatentability based on obviousness and statutory deficiencies, particularly regarding the combination of prior art references.
POSCO Co., Ltd. et al. v.ArcelorMittal
POSCO Co., Ltd. successfully petitioned the PTAB to institute an IPR against ArcelorMittal's patent, demonstrating a reasonable likelihood of prevailing on all 25 challenged claims. The Board found sufficient evidence across multiple grounds of obviousness (103) involving various prior art combinations.
POSCO Co., Ltd. et al. v.ArcelorMittal
POSCO Co., Ltd. successfully convinced the PTAB to institute an IPR against ArcelorMittal's patent (10961602) regarding coated steel/aluminum alloys for automotive parts. The Board found a reasonable likelihood of prevailing on multiple grounds, instituting the challenge across 30 claims.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
Stingray Group Inc. successfully secured institution of its IPR challenge against a patent covering multimedia content delivery systems. The Board found that Petitioner established a reasonable likelihood of prevailing across multiple grounds under 35 U.S.C. §§ 102 and 103, moving the case to the merits phase.
Tesla, Inc. v.Intellectual Ventures II LLC
The PTAB denied Tesla's IPR against Intellectual Ventures II over patent 7,181,743. The Board found that the prior art did not teach or suggest the specific 'event correlation capabilities' required by the challenged claims.
Twitch Interactive, Inc. et al. v.Razdog Holdings LLC
Twitch Interactive successfully challenged a patent claim in the PTAB, demonstrating a reasonable likelihood of prevailing on obviousness grounds. The Board adopted Petitioner's narrow construction of 'real time,' favoring transmission upon availability without significant delay over strict human-perception timing.
Twitch Interactive, Inc. et al. v.Razdog Holdings LLC
Twitch Interactive successfully secured institution of its § 103 IPR challenge against Razdog Holdings LLC's patent. The Board adopted the Petitioner's interpretation of 'real time,' allowing the case to proceed to trial on all claims.
M/S GREENPLY INDUSTRIES LTD. v.M/S EVERGREEN VENEERS PVT. LTD.
The plaintiff, Greenply Industries Ltd., filed a suit seeking permanent injunction for alleged infringement of its registered trade mark 'GREEN' against the defendant, Evergreen Veneers Pvt. Ltd., who was using the mark 'EVERGREEN' on similar goods (plywood products). The court examined issues of delay and trademark similarity.
Evergreen Sweet House v.JV Evergreen Sweets And Treats & Ors.
The Delhi High Court granted an interim injunction in favor of Evergreen Sweet House against JV Evergreen Sweets And Treats. The court found a prima facie case of passing off, noting that the plaintiff has been operating under the 'Evergreen' mark since 1963, establishing significant goodwill and prior use. Given the defendant's recent entry into the market and the likelihood of customer confusion on food delivery platforms, the court restrained the defendants from using the infringing mark until the final suit adjudication.
Saint Gobain Construction Products UK Ltd. v.Mr.Tallam Uma Shankar Gupta
The Madras High Court allowed a petition seeking rectification of the Trade Marks Register, directing the removal of the mark 'GYPLOCK' (No. 3536418). The petitioner, Saint Gobain Construction Products UK Ltd., successfully argued that its established trademark 'GYPROC' was similar to the impugned mark and used on identical goods—building materials. Despite arguments regarding common trade terms ('GYP'), the court found the overall similarity between 'GYPROC' and 'GYPLOCK' likely to cause confusion, thereby protecting the purity of the register.
G. Pohl-Boskamp GmbH & C. KG v.pharma-aktiva GmbH, ALDI SÜD Dienstleistungs-SE & Co. oHG, ALDI Nord Deutschland Stiftung & Co. KG, ALDI SE & Co. KG, Hofer Kommanditgesellschaft
G. Pohl-Boskamp GmbH & C. KG, the proprietor of European Patent EP 1 993 363 B1 concerning a composition for combating ectoparasites and their eggs, sought interim measures against pharma-aktiva GmbH and several Aldi/Hofer entities for alleged infringement through the sale of a competing lice spray. The Local Chamber Mannheim of the Unified Patent Court granted the interim measures in part, ordering the respondents to cease certain manufacturing, offering, and distribution activities in Germany and Austria, with penalties of EUR 100 per unit for violations, and to surrender infringing products in their possession.
Alexion Pharmaceuticals, Inc. v.Samsung Bioepis NL B.V.
The Court of Appeal of the Unified Patent Court rejected Alexion Pharmaceuticals' appeal against the dismissal of its application for provisional measures against Samsung Bioepis concerning European Patent EP 3 167 888 B1 for a C5-binding antibody (eculizumab) used to treat paroxysmal nocturnal hemoglobinuria. The court held that the patent's claim 2 could not be corrected by interpretation to remove 22 extra amino acids at the N-terminus of SEQ ID NO:4, as the existence of the error and the precise correction were not sufficiently certain to the person skilled in the art. Consequently, the court found it more likely than not that claim 2 was insufficiently disclosed under Art. 83 EPC, and ordered Alexion to bear the costs of the appeal proceedings.
HARTING Electric Stiftung & Co. KG (Application for Access to Court Files) v.Ex Parte
HARTING Electric Stiftung & Co. KG, an opponent in pending opposition proceedings before the European Patent Office concerning European Patent EP 3 602 692, applied for access to the briefs and evidence filed in infringement proceedings between PHOENIX CONTACT GmbH & Co. KG and Industria Lombarda Materiale Elettrico I.L.M.E. S.p.A. and ILME GmbH before the Local Division Munich. The court granted the application, holding that an opponent in pending opposition proceedings has a legal interest in accessing court files under Rule 262.1(b) RoP during ongoing proceedings.
Edwards Lifesciences Corporation v.Meril GmbH, Meril Life Sciences Pvt. Ltd., Meril Italy S.r.l.
Procedural order in a patent infringement action concerning European patent EP 3669828 before the Local Division Munich. The court granted both parties' Rule 263 requests to add Romania (which acceded to the Unitary Patent system on 1 September 2024) to the infringement action and counterclaim for revocation, and granted the claimant's request to amend its information request to require purchase documents. The court set the dispute value at €16 million, scheduled the oral hearing for 11 February 2025, and rejected requests for party and court experts.
10x Genomics, Inc. and President and Fellows of Harvard College v.Vizgen, Inc.
This is a procedural order from the Local Chamber Hamburg of the Unified Patent Court in an infringement action concerning EP4108782. The court confirmed the judge-rapporteur's rejection of Harvard's third request to amend the patent, holding that under Rule 30.2 RoP, a delay of approximately three months between the reason for the amendment (the EPO Opposition Division's preliminary opinion of August 2, 2024) and the filing of the request (October 25, 2024) was too long. The court ruled that the patent proprietor's subjective expectations regarding procedural delay are irrelevant, and the question must be assessed objectively.
Alexion Pharmaceuticals, Inc. v.Amgen Technology (Ireland) Unlimited Company, Amgen N.V., Amgen GmbH, Amgen AB, Amgen S.A.S., Amgen s.r.l., Amgen Biofarmacêutica Lda., Amgen Zdravila D.O.O.
Alexion Pharmaceuticals, the proprietor of European Patent 3 167 888 B1 relating to the antibody eculizumab for treating paroxysmal nocturnal hemoglobinuria, sought provisional measures against Amgen, which markets BEKEMV®, a biosimilar of Soliris®. The Court of First Instance (Hamburg Local Division) dismissed Alexion's application, and Alexion appealed. The Court of Appeal rejected the appeal, holding that the patent's SEQ ID NO:4 sequence must be interpreted as including 22 extra amino acids at the N-terminus, and that Alexion had failed to demonstrate with sufficient certainty that the skilled person would correct this as an error, rendering the patent claim more likely than not insufficiently disclosed under Art. 83 EPC.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB granted institution of IPR2025-00350 on June 13, 2025. A director‑review request filed by the patent owner on July 13 was deemed untimely and will not be considered.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB notified parties that Director Review requests for three IPRs have been received. The petitioner has five business days to submit a concise response limited to the raised issues, with no new evidence allowed.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
The PTAB issued an institution decision for IPR2025-00349 on June 13, 2025. A later director‑review request by the patent owner was filed after the 14‑day deadline and was deemed untimely, so the Board will not consider it.
Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.
The PTAB instituted an inter partes review of DISH Technologies' adaptive streaming patent and granted joinder of Czech challenger Webgroup and NKL Associates, linking the case to a prior IPR over the same claims.
Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.
The USPTO denied Webgroup Czech Republic's request for Director Review of the Final Written Decisions in two IPRs challenging DISH Technologies patents.
Webgroup Czech Republic, a.s. et al. v.DISH Technologies L.L.C. et al.
The PTAB instituted inter partes review of DISH Technologies' adaptive‑bitrate streaming patent (claims 1‑16) and granted joinder to Webgroup Czech Republic and NKL Associates, aligning the case with the earlier fuboTV/MasterClass IPR.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch filed a joint request to keep their settlement agreement confidential, invoking federal statutes. The Board had previously authorized the filing, and the parties seek limited disclosure only to government agencies or parties with good cause.
Stingray Group Inc. et al. v.Hernandez-Mondragon, Edwin et al.
An email from the PTAB Director informs parties of Director Review requests for IPR2025-00349, -00350, and -00351, outlining a five‑page, five‑day response limit and prohibiting new evidence.
Microsoft Corporation v.EyesMatch Ltd.
Microsoft and EyesMatch have settled their IPR dispute over U.S. Patent 8,982,110, filing a joint motion to terminate the proceeding.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.